Kidney Week 2019 — Atrasentan reduces the risk of renal events in T2D and chronic kidney disease


  • Marielle Fares, Pharm.D.
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Atrasentan reduced the risk of renal events in patients with type 2 diabetes (T2D) and chronic kidney disease.
  • In patients with T2D at high risk of end-stage renal disease, selective endothelin receptor antagonists may protect renal function.

Why this matters

  • Treatment with a low-dose endothelin A receptor antagonist in T2D reduces albuminuria without causing sodium retention, but long treatment effects on renal outcomes are unknown.

Study design

  • Double-blind, randomized, placebo-controlled, multicenter trial of adults with T2D with an estimated glomerular filtration rate (eGFR) of 25-75 mL/minute/1.73 m2 and a urine albumin to creatinine ratio (UACR) of 300-5000 mg/g who had received renin-angiotensin inhibitors for 4 weeks.
  • Oral atrasentan 0.75 mg daily was given for enrichment period to assess response.
  • Responders (patients with 30% decrease in UACR and no substantial fluid retention) (n=2648) were randomly assigned to receive atrasentan or placebo.
  • Primary endpoint was a composite of doubling of serum creatinine for ≥30 days, end-stage kidney disease (eGFR 15 mL/minute/1.73 m2 for 90 days), chronic dialysis for >90 days, kidney transplantation, or death from kidney failure in responders.

Key results

  • At the median follow-up of 2.2 years, the composite renal endpoint had occurred in 79 (6%) atrasentan patients and 105 (7.9%) placebo patients (HR 0.65; 95% CI, 0.49-0.88; P=.0047).
  • Fluid retention and anaemia were observed in atrasentan group; hospital admission for heart failure occurred in both groups (3.5%, n=47 in atrasentan vs 2.6%, n=34 in placebo group) (HR 1.33; 95% CI, 0.85-2.07; P=.208).